TICKERNERD
Menu
TARSTARSHealthcare · Biotechnology

TARS Stock Forecast: Tarsus Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$61
+3.86% on the day

The 9 Wall Street analysts covering Tarsus Pharmaceuticals, Inc. hold a median 12-month price target of $95 — +54.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.6B
Ticker Nerd rank
79 / 100
Median analyst target
$95
Analysts covering
9
Total return, dividends reinvested
1W
+2.0%
1M
−6.3%
YTD
−25.1%
1Y
+50.3%
From 52W high
−25.7%
From 52W low
+49.0%
$41
$83
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TARS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tarsus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
98
Quality
96
Growth
80
Momentum
64
Revisions
50
Accruals
44
Size
33
Issuance
23

Volatility (98): The share price has been relatively steady.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Tarsus Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

TARS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TARS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100Oct 25Jan 26Apr 26Jul 26TARSHigh $104Median $95Low $88

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $88Median $95High $104

The green dot is the last close — the median target sits +54.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 July 2026MizuhoMaintainsOutperform$100 → $98
21 July 2026GuggenheimMaintainsBuy$90 → $89
21 July 2026GuggenheimMaintainsBuy—
9 July 2026HC Wainwright & Co.ReiteratesBuy—
9 July 2026HC Wainwright & Co.ReiteratesBuy$88
4 May 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026GuggenheimMaintainsBuy—
25 Feb 2026OppenheimerMaintainsOutperform—
9 Dec 2025BarclaysInitiatesOverweight—
20 Nov 2025MizuhoInitiatesOutperform—
5 Nov 2025GuggenheimMaintainsBuy—
20 Oct 2025HC Wainwright & Co.MaintainsBuy—
27 May 2025HC Wainwright & Co.AssumesBuy$72
5 May 2025Goldman SachsMaintainsNeutral—
2 May 2025GuggenheimMaintainsBuy—
6 Mar 2025JefferiesMaintainsBuy—
26 Feb 2025BarclaysMaintainsOverweight—
26 Feb 2025GuggenheimMaintainsBuy—
26 Feb 2025HC Wainwright & Co.ReiteratesBuy—
24 Feb 2025GuggenheimReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TARS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Tarsus Pharmaceuticals, Inc. (TARS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−37.1×

Cheaper than 98% of US stocks

Price / sales
4.8×

Cheaper than 26% of US stocks

Price / book
7.3×

Cheaper than 14% of US stocks

EV / EBITDA
−45.7×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
106.9%

Higher than 94% of US stocks

Earnings growth (YoY)
106.9%

Higher than 87% of US stocks

Gross margin
94.2%

Higher than 98% of US stocks

Operating margin
−3.8%

Higher than 31% of US stocks

Net margin
−9.0%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−14.0%

Higher than 34% of US stocks

Return on assets
−5.9%

Higher than 30% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TARS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TARSTarsus Pharmaceuticals, Inc.$2.6B
79
IMNMImmunome, Inc.$2.5B
49
KODKodiak Sciences, Inc.$2.5B
55
RAREUltragenyx Pharmaceutical, Inc.$2.5B
38
TRVITrevi Therapeutics, Inc.$2.6B
53
BEAMBeam Therapeutics, Inc.$2.6B
64
ATAIAtai Beckley, Inc.$2.6B
35
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TARS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TARS news & analysis

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks Investment Research · 29 July 2026negative

According to Zacks Investment Research, Tarsus Pharmaceuticals may report negative earnings for Q2 as it lacks the key ingredients for a likely earnings beat. The article advises investors to prepare for the upcoming quarterly release.

Why it matters — A TARS watcher would care because the report suggests the company may underperform earnings expectations, which could impact the stock's near-term performance.

Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching

Seeking Alpha · 24 July 2026neutral

Tarsus saw a Q1 2026 sales dip for Xdemvy, its first since launch, but reiterated full-year 2026 net sales guidance of $670M–$700M, with Q2 prescription data suggesting a potential recovery. The company also acquired iRenix Medical, adding IRX-101 to its pipeline.

Why it matters — A TARS watcher would care about the Q1 sales dip and whether Q2 data signals a rebound that lets the company hit its annual Xdemvy guidance, plus the early-stage pipeline addition from the iRenix acquisition.

FAQ

Frequently asked questions about TARS stock

What is the TARS stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Tarsus Pharmaceuticals, Inc. have a median 12-month price target of $95, with estimates ranging from $88 to $104. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TARS stock a buy right now?

Of the 9 analysts covering Tarsus Pharmaceuticals, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tarsus Pharmaceuticals, Inc. 79 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TARS?

As at 1 Aug 2026, Tarsus Pharmaceuticals, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will TARS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +54.9% from the last close, and Ticker Nerd's factor model ranks Tarsus Pharmaceuticals, Inc. 79 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TARS stock forecast for 2030?

No analyst covering Tarsus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TARS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $88 to $104 over the next 12 months.

How has TARS stock performed over the past year?

Tarsus Pharmaceuticals, Inc. returned +50.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tarsus Pharmaceuticals, Inc. do?

Tarsus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for the treatment of ophthalmic conditions.

What is the latest news on TARS?

The most recent item we track (Zacks Investment Research, 29 July 2026): "Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release". According to Zacks Investment Research, Tarsus Pharmaceuticals may report negative earnings for Q2 as it lacks the key ingredients for a likely earnings beat. The article advises investors to prepare for the upcoming quarterly release.

Company

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for the treatment of ophthalmic conditions. The company’s primary focus is on innovative treatments that address significant unmet medical needs in eye care, particularly in diseases affecting the anterior segment of the eye. Central to its portfolio is a targeted, investigational compound aimed at treating Demodex blepharitis, a common eyelid condition. Tarsus leverages advanced diagnostic tools and delivery mechanisms to enhance the efficacy and safety of its therapeutic candidates. Positioned within the dynamic biopharmaceutical industry, Tarsus Pharmaceuticals supports healthcare innovation by bridging gaps in available ophthalmic therapies. By prioritizing both patient outcomes and physician needs, the company plays a crucial role in the medical field, pushing boundaries in drug development and offering potential transformative solutions for eye health. Headquartered in Irvine, California, Tarsus continues to collaborate with researchers and clinical experts to advance its robust pipeline, reinforcing its commitment to addressing diverse ophthalmological challenges worldwide.

CEO Dr. Bobak R. Azamian M.D. · 370 employees · United States · https://tarsusrx.com